List view / Grid view
8 March 2016 | By Victoria White
Upon concluding their joint venture, Sanofi Pasteur and MSD plan to integrate their respective European vaccine businesses into their operations...
16 February 2016 | By Victoria White
A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
21 December 2015 | By Victoria White
MSD has announced results from the Phase 2/3 KEYNOTE-010 study of Keytruda (pembrolizumab) in patients with previously treated non-small cell lung cancer (NSCLC)...
10 November 2015 | By Victoria White
The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)...
9 October 2015 | By Victoria White
This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab...
7 October 2015 | By
Pembrolizumab was the first drug to be approved through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS)...
7 September 2015 | By Victoria White
NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...
30 June 2015 | By Victoria White
MSD recently announced the primary results of the TECOS trial, a placebo-controlled study of the cardiovascular safety of MSD’s DPP-4 inhibitor, sitagliptin...
26 June 2015 | By Victoria White
The EC has approved Simponi (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA)...
17 June 2015 | By Victoria White
GARDASIL 9 is approved in the EU for active immunisation against premalignant lesions and cancers affecting the cervix, vulva, vagina or anus...
10 June 2015 | By Victoria White
MSD has announced additional data from a subanalysis of the GO-AHEAD study on the effect of Simponi in treating patients with nr-axial SpA...
15 December 2014 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
19 November 2014 | By MSD
Application for approval of new indication for golimumab has been filed with the European Medicines Agency...
13 October 2014 | By MSD
NICE draft guidance says no to biologic treatments for patients with moderate-to-severe ulcerative colitis – potentially missing the opportunity to provide an alternative...
